

WATKINS et al.

Appl. No.: To Be Assigned

US National Phase of PCT/GB03/01463

September 30, 2004


AMENDMENTS TO THE ABSTRACT:

Please insert the attached ABSTRACT after the claims.

ABSTRACT

CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:



wherein: Cy is independently a cyclyl group; Q^1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J^1 is independently a covalent bond or $-\text{C}(=\text{O})-$; J^2 is independently $-\text{C}(=\text{O})-$ or $-\text{S}(=\text{O})_2-$; Q_2 is independently an acid leader group; wherein: Cy is independently: C_3 - $_{20}$ carbocyclyl, C_3 - $_{20}$ heterocyclyl, or C_5 - $_{20}$ aryl; and is optionally substituted; Q^1 is independently: a covalent bond; C_{1-7} alkylene; or C_{1-7} alkylene-X- C_{1-7} alkylene, $-\text{X}-\text{C}_{1-7}$ alkylene, or C_{1-7} alkylene-X-, wherein X is $-\text{O}-$ or $-\text{S}-$; and is optionally substituted; Q^2 is independently: C_{4-8} alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q^2 is independently: C_{5-20} arylene; C_{5-20} arylene- C_{1-7} alkylene; C_{1-7} alkylene- C_{5-20} arylene; or, C_{1-7} alkylene- C_{5-20} arylene- C_{1-7} alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.